Improving Access to Therapy for Patients With Inborn Errors of Immunity: A Call to Action.
J Allergy Clin Immunol Pract
; 11(6): 1698-1702, 2023 06.
Article
en En
| MEDLINE
| ID: mdl-37119982
ABSTRACT
Breakthroughs in sequencing technology, targeted immunotherapy, and immune reconstituting treatment have increased the pool of patients with inborn errors of immunity, requiring expertise from clinical immunologists. A growing category of immunodeficiency, presenting as primary immune regulatory disorder and secondary immunodeficiency due to targeted immune therapy for cancer and autoimmunity, has added to the growing burden of patients needing access to immune-supportive therapy. The confluence of a growing population of patients needing a clinical immunologist, complex payer structures, and inadequate health care representation will exacerbate current problems with access to therapy. Patients, health care providers, researchers, public and private payers, and industry must come together to find solutions to improve access to therapy. In this article, we reviewed the major topics regarding access to therapy for patients with immunodeficiency.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Pacientes
/
Inmunoterapia
Límite:
Humans
Idioma:
En
Revista:
J Allergy Clin Immunol Pract
Año:
2023
Tipo del documento:
Article